ArticleGels (Basel, Switzerland)2024
Natrium Alginate and Graphene Nanoplatelets-Based Efficient Material for Resveratrol Delivery.
Article in Gels (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Engineering alginate hydrogels loaded with resveratrol as a dual platform for cancer therapy and wound regeneration.Discover nano · 2026Review
- Multifunctional Nanomaterials for Precision Diagnostics and Drug Delivery: AI-Assisted Biosensing, Barrier-Directed Transport, Stimuli-Responsive Release, and Theranostic Integration.Molecules (Basel, Switzerland) · 2026Review
- Hybrid Alginate-Graphene Composites: Biochemical Features and Biomedical Potential.Marine drugs · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, alginate-based composite beads were developed for the delivery of resveratrol, a compound with therapeutic potential. Two formulations were prepared: one with sodium alginate and resveratrol (AR) and another incorporating graphene nanoplatelets (AGR) to improve drug release control. The beads were formed by exploiting alginate's ability to gel via ionic cross-linking. For the AGR formulation, sodium alginate was dissolved in water, and graphene was dispersed in isopropyl alcohol to achieve smaller flakes. Resveratrol was dissolved in an ethanol/water mixture and added to the graphene dispersion; the resulting solution was mixed with the alginate one. For the AR formulation, the resveratrol solution was mixed directly with the alginate solution. Both formulations were introduced into a calcium chloride solution to form the beads. The release of resveratrol was studied in phosphate-buffered saline at different pH values. Results showed that the presence of graphene in the AGR sample increased drug release, particularly at pH 6.8, indicating a pH-driven release mechanism. Kinetic analysis revealed that the Higuchi model best describes the release mechanism. Finally, cytotoxicity tests showed the biocompatibility of the system in normal human cells. These findings suggest that graphene-enhanced alginate matrices have significant potential for controlled drug delivery applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.